☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Luxturna
Novartis's Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Re...
October 16, 2020
Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease
November 26, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.